Medical Advocates
Nevirapine (Viramune)
 
Perinatal/Neonate Main Page

New and Noteworthy      National Studies
General Reports
Pharmacokinetics
Safety
Efficacy
 Resistance
Viral Dynamics
Adverse Events
Diagnostics
NVP Detection
 Cost Effectiveness
 NVP Donation Information
NVP  Main Page  Main New/Newsworthy

Home Page

  

 

  
Last Update:  August 23, 2008
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
New and Noteworthy
 
August 2008
 
July 2008
 
General Reports
 
      Internet
 
 
Boehringer Ingelheim provides key background on nevirapine
December 15, 2004
 News Release
 
HIVET 012 Study and the Safety and Effectiveness of Nevirapine in Preventing
Mother-to-Infant Transmission of HIV
 NIAID
News Release

FULL-TEXT ARTICLE
 Effects of PMTCT with Nevirapine on Women
Coffey  S
AIDSinfo  02/23/2004
 Paper

FULL-TEXT REPORT
Prevention of Mother-to-Child Transmission of HIV: Selection and Use of Nevirapine
(Technical Notes)
 (Family and Community Health Cluster, Department of HIV/AIDS, WHO, May 2001).
Report

     Journal Papers, Abstracts, and Commentaries

 
Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding
in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials.
 Six Week Extended-Dose Nevirapine (SWEN) Study Team.
Lancet. 2008 Jul 26;372(9635):300-313.
 Abstract
 
Nevirapine concentrations in newborns receiving an extended prophylactic regimen.
 Mirochnick M, Nielsen-Saines K, Pilotto JH, et al 
J Acquir Immune Defic Syndr. 2008 Mar 1;47(3):334-7.
 Abstract
 
Transmission Rates in Consecutive Pregnancies Exposed to Single-Dose Nevirapine in
Soweto, South Africa and Abidjan, Cote d'Ivoire.
 Martinson NA, Ekouevi DK, Dabis F, et al
J Acquir Immune Defic Syndr. 2007 Apr 12
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Stability of Nevirapine Suspension in Prefilled Oral Syringes Used for Reduction of Mother-
to-Child HIV Transmission.
 Rexroad VE, Parsons TL, Hamzeh FM,et al 
J Acquir Immune Defic Syndr. 2006 Sep 21;
 Abstract
 
Enzyme Inducers Reduce Elimination Half-Life After a Single Dose of Nevirapine in Healthy
Women.
 L'homme RF, Dijkema T, van der Ven AJ, Burger DM 
J Acquir Immune Defic Syndr. 2006 Aug 24;
 Abstract
 
Controversies in the use of nevirapine for prevention of mother-to-child transmission of HIV.
McIntyre JA. 
Expert Opin Pharmacother. 2006 Apr;7(6):677-85.
Abstract
 
Transmission of Human Immunodeficiency Virus Type 1 Nevirapine Resistance Mutaton
K103Nfrom a Treatment-Naive Mother to her Child
 Schmitz T, Kleinkauf N, Klempa B, et al 
Pediatr Infect Dis J. 2006 Mar;25(3):275-276
 Abstract

Should nevirapine be used to prevent mother-to-child transmission of HIV among
women of unknown serostatus?
 Sint TT, Dabis F, Kamenga C, et al 
Bull World Health Organ. 2005 Mar;83(3):224-228.
 Abstract
 
  Constraints of implementing on a larger scale the protocol of prevention of HIV/AIDS from
mother to child by Nevirapine intake
 Adeothy-Koumakpai S, Monnykosso CN,  D'almeida M, et al 
Arch Pediatr. 2004 Dec;11(12):1425-1429.
Abstract

 Intrapartum Exposure to Nevirapine and Subsequent Maternal Responses to
Nevirapine-Based Antiretroviral Therapy.
 Jourdain G, Ngo-Giang-Huong N, Le Coeur S, et al
N Engl J Med. 2004 Jul 9
 Abstract
 
  Nevirapine: a review of its use in the prevention and treatment of paediatric
HIV infection.
Bardsley-Elliot A, Perry CM.
Paediatr Drugs 2000 Sep-Oct;2(5):373-407
Abstract 
 

          Conference Reports, Abstracts, and Posters
 
 
Low Birth Weight with Nevirapine-based ART in Abidjan, Côte d’Ivoire: The ANRS Ditrame Plus
Cohort and MTCT-Plus Initiative, 2001 to 2007
 DK Ekouevi, B Tonwe-Gold, R Becquet, et al
 (15th CROI)
 Abstract
 
Risks Associated with Nevirapine Use in Pregnant and Non-pregnant Women
 E Aaro, M Kempf, S Criniti, et al
 (15th CROI)
 Abstract

Is stopping zidovudine/single-dose nevirapine safer than stopping combination antiretroviral
treatment in women after delivery who do not require therapy for their own health?
 Phanuphak N, Apornpong T, Limpongsanurak S, et al
 (4th IAS  Conference)
 Abstract
 
African Infants’ CC Chemokine Ligand 3-like 1 Gene Copy Numbers Influence the Risk of
Perinatal HIV Transmission Only in the Absence of Maternal Nevirapine
 L Kuhn, D Schramm, S Donninger, et al
(14 CROI)
 Abstract
 
Injectable sustained release nevirapine, designed to be co-administered in programs of
accelerated DPT immunization, for the prevention of mother-to-child HIV transmission
associated with breast feeding
Smith T., Sullivan J.L., Neely M., et al
 (XVI International AIDS Conference)
 Abstract
 
Mucosal exposure to HIV-1 does not lead to intrapartum transmission after nevirapine
single dose
Kunz A., Mugenyi K., Karcher H., et al
(XVI International AIDS Conference)
 Abstract
 
POSTER
 Post-partum Interruption of a Triple Drug Regimen Containing Nevirapine for Prevention of
Mother-to-Child HIV Transmission Does Not Select the K103N Mutation
 H  Pere, M Vignoles, N Laufer, et al 
(13 CROI)
 PDF Poster   Abstract

Virologic Response to NNRTI Treatment among Women Who Took Single-dose Nevirapine
18 to 36 Months Earlier
 A Coovadia, B Marais, E Abrams,  et al  
(13 CROI)
 Abstract 

Timing of maternal and infant nevirapine and the risk of mother-to-child transmission of
HIV-1: HIVNET 024
 BH. Chi, L Wang,  JS Read   M Sheriff
(3rd IAS)
Abstract 

Association of Cord Blood Nevirapine with Self-reported Timing of Dose and HIV-1
Transmission in the HIV NET 012 Study
 B Jackson, T Parsons, P Musoke, et al
(12 CROI)
Abstract 

NEVIRAPINE TOLERABILITY IN HIV INFECTED WOMEN IN PREGNANCY -
A WORD OF CAUTION 
F. Lyons, S. Hopkins, A. Mc Geary, et al
 (2nd IAS)
 Abstract
 
In vivo human placental transfer of nevirapine and protease inhibitors and its
detection in amniotic fluid
A Gingelmaier, M Kurowski, R Kaestner
 (15IAC)
 Abstract
Pharmacokinetics
               

       Journal Papers, Abstracts, and Commentaries

 
Chronic administration of nevirapine during pregnancy: impact of pregnancy on
pharmacokinetics.
 Capparelli EV, Aweeka F, Hitti J, et al 
HIV Med. 2008 Apr;9(4):214-220.
 Abstract 
 
Steady-state nevirapine plasma concentrations are influenced by pregnancy.
 Nellen JF, Damming M, Godfried MH 
HIV Med. 2008 Apr;9(4):234-8.
 Abstract 

Nevirapine: pharmacokinetic considerations in children and pregnant women.
Mirochnick M, Clarke DF, Dorenbaum A.
Clin Pharmacokinet 2000 Oct;39(4):281-93
Abstract 

Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected
pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250
Team.
Mirochnick M, Fenton T, Gagnier et al .
J Infect Dis 1998 Aug;178(2):368-74
Abstract

A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected
pregnant Ugandan women and their neonates (HIVNET006).
Musoke P, Guay LA, Bagenda D, et al,
AIDS 1999 Mar 11;13(4):479-86  
Abstract

  

          Conference Reports, Abstracts, and Posters

 
POSTER
 Nevirapine Pharmacokinetics with an Extended Prophylactic Regimen during the First 2 Weeks
of Life
 M Mirochnick, K Nielsen, J Pilotto, et al 
(13 CROI)
 PDF Poster    Abstract 
 
Modeling the sexual transmission of HIV-1 strains resistant to nevirapine from MTCT
programs
A Medley, K O'Reilly, G Schmid, M D Swea
 (15IAC)
 Abstract
 
Nevirapine plasma exposure is decreased in pregnant women
A Haberl, N Hentig, A Carlebach, et al
 (15IAC)
 Abstract
 
Nevirapine and different protease inhibitors - pharmacokinetics and placental
transfer at the delivery of HIV-positive women
A Gingelmaier, T A Grubert, M Kurowski, et al
 (15IAC)
 Abstract
 
PLASMA AND INTRACELLULAR PHARMACOKINETICS OF NEVIRAPINE
S Azoulay, MC Nevers, C Creminon, et al
 (2nd IAS)
 Abstract
 
CHANGES IN NEVIRAPINE PLASMA CONCENTRATIONS ALONG 48 WEEKS AND
RELATIONSHIP WITH TRANSAMINASE ELEVATIONS
D. González de Requena, I. Jiménez, et al
 (2nd IAS)
 Abstract
 
Population Pharmacokinetics of Low-dose Nevirapine for Prevention of Breast Milk HIV
Transmission in Infants from Birth through 6 Months of Age
M Mirochnick, E Capparelli, Suzette Blanchard, et al    
(11 CROI)
 Abstract
 
Steady State Nevirapine Pharmacokinetics during Second and Third Trimester Pregnancy
and Postpartum: PACTG 1022
F Aweeka, P Lizak, L Frenkel, et al   
(11 CROI)
 Abstract
Adherence
 

      Journal Papers, Abstracts, and Commentaries
 
A WEEK-IN-REVIEW FEATURED REPORT
Predictors of Nonadherence to Single-Dose Nevirapine Therapy for the Prevention of
Mother-to-Child HIV Transmission.
 Albrecht S, Semrau K, Kasonde P, et al
J Acquir Immune Defic Syndr. 2006 Jan 1;41(1):114-118
Abstract
 
Adverse Events
 

         Journal Papers, Abstracts, and Commentaries

 
Serious toxicity associated with continuous nevirapine-based HAART in pregnancy.
 van Schalkwyk JE, Alimenti A, Khoo D, et al
BJOG. 2008 Sep;115(10):1297-302.
 Abstract
 
Nevirapine-induced side effects in pregnant women: experience of a Brazilian university
hospital.
Kondo W, Carraro EA, Prandel E, et al
 Braz J Infect Dis. 2007 Dec;11(6):544-8.
 Abstract
 
Nevirapine-associated toxicity in HIV-infected Thai men and women, including pregnant
women.
Phanuphak N, Apornpong T, Teeratakulpisarn S, et al
HIV Med. 2007 Sep;8(6):357-66.
 Abstract
 
Effects of Nevirapine, Compared with Lamivudine, on Lipids and Lipoproteins in HIV-1-
Uninfected Newborns: The Stopping Infection from Mother-to-Child via Breast-Feeding
in Africa Lipid Substudy.
 Sankatsing RR, Wit FW, Pakker N, et al
J Infect Dis. 2007 Jul 1;196(1):15-22.
 Abstract
 
Antiretroviral-Associated Toxicity Among HIV-1-Seropositive Pregnant Women in
Mozambique Receiving Nevirapine-Based Regimens.
Jamisse L, Balkus J, Hitti J, et al
J Acquir Immune Defic Syndr. 2007 Jan 25;
 Abstract
 
Maternal hepatotoxicity with nevirapine as part of combination antiretroviral therapy
in pregnancy.
 Lyons F, Hopkins S, Kelleher B, et al  
HIV Med. 2006 May;7(4):255-60.
 Abstract
 
Nevirapine toxicity in a cohort of HIV-1-infected pregnant women.
 Joao EC, Calvet GA, Menezes JA, et al 
Am J Obstet Gynecol. 2006 Jan;194(1):199-202
 Abstract

hird-Trimester Maternal Toxicity With Nevirapine Use in Pregnancy.
 Joy S, Poi M, Hughes L, Brady MT,
Obstet Gynecol. 2005 Nov;106(5):1032-1038.
 Abstract
 
Nelfinavir and nevirapine side effects during pregnancy.
 Timmermans S, Tempelman C, Godfried MH 
AIDS. 2005 May 20;19(8):795-799.
Abstract
 
Maternal Toxicity With Continuous Nevirapine in Pregnancy: Results From PACTG
1022.
 For the PACTG 1022 Study Team .
J Acquir Immune Defic Syndr. 2004 Jul 1;36(3):772-776.
 Abstract

Effect of nevirapine toxicity on choice of perinatal HIV prevention strategies.
Stringer JS, Sinkala M,  Rouse DJ, et al.
Am J Public Health 2002 Mar;92(3):365-6
 Abstract
 

  
          Conference Reports, Abstracts, and Posters
 
 
POSTER
 Toxicities from Nevirapine-based ART Regimens in Pregnant Women with CD4 Count
between250 and 350 Cells/mm3
N Phanuphak, T Apornpong, S Limpongsanurak, et al
 (14 CROI)
 PDF Poster    Abstract 
 
Nevirapine-associated hepatic toxicity among HIV-1-seropositive pregnant women in
Mozambique
Jamisse L., Balkus J., Hitti J., et al
 (XVI International AIDS Conference)
 Abstract
 
Adverse reactions related to antiretroviral regimen containing nevirapine used by HIV-infected
pregnant women from the maternal and perinatal cohort of Belo Horizonte, Brazil
Aguiar R.A.L.P., Melo V.H., Cavallo I.K.D., et al
 (XVI International AIDS Conference)
 Abstract
 
Toxicity of nevirapine in HIV-infected women with high CD4 counts in Malawi: the BAN study
Bramson B., Chasela C., Chavula C., et al
 (XVI International AIDS Conference)
 Abstract
 
Risk of discontinuation of nevirapine due to toxicities in antiretroviral naive and experienced patients
with high and low CD4 counts
 Mocroft A., Lacombe K., Rockstroh J , et al 
(XVI International AIDS Conference)
 Abstract

A Comparison of Toxicity in Nevirapine- vs Protease Inhibitor-containing HAART
Regimens in Pregnant Women
 D Money, D Khoo, G MacDonald,  et al
(12 CROI)
Abstract

Preliminary Findings: Incidence of Serious Adverse Events Attributed to Nevirapine among
Women Enrolled in an Ongoing Trial Using HAART tor Prevent Mother-to-Child HIV
Transmission
 T Thomas, P Amornkul, J Mwidau, et al
(12 CROI)
Abstract
 
Nevirapine toxicity in the obstetrical population when used in combination with other antiretrovirals
A Gonzalez-Garcia, MI Fernandez, A Cotter
 (15IAC)
Abstract
 
Evaluation of nevirapine toxicity in a cohort of HIV-1 infected pregnant women
EC Joao, GA Calvet, JA Menezes, et al
 (15IAC)
Abstract
Diagnostics/Monitoring
 
         Journal Papers, Abstracts, and Commentaries
 
  Sensitive Drug-Resistance Assays Reveal Long-Term Persistence of HIV-1 Variants with the
K103N Nevirapine (NVP) Resistance Mutation in Some Women and Infants after the
Administration of Single-Dose NVP: HIVNET 012.
 Flys T, Nissley DV, Claasen CW,
J Infect Dis. 2005 Jul 1;192(1):24-9.
 Abstract
NVP Detection Studies
 

          Conference Reports, Abstracts, and Posters

 
Nevirapine is detectable in breast milk up to 2 weeks after single dose
Kunz A., Mugenyi K., Karcher H., et al
 (XVI International AIDS Conference)
 Abstract

Nevirapine concentration in cervico-vaginal and oropharyngeal secretions in
a mother-child cohort in Uganda
Kunz A., Karcher H., Mayer A., et al
 (3rd IAS)
Abstract

  
Economics
 
         Journal Papers, Abstracts, and Commentaries
 
  Cost-effectiveness of nevirapine to prevent mother-to-child HIV transmission in eight
African countries.
 Sweat MD, O'Reilly KR, Schmid GP, et al   
AIDS. 2004 Aug 20;18(12):1661-71
 Abstract
 
          Conference Reports, Abstracts, and Posters
 
  Modeling the Effectiveness of Nevirapine(NVP), HIV Vaccine and HIV-Specific
Monoclonal Antibody( HIV-Ab) on Mother to Child Transmission of HIV from Intrapartum
and Breast-Feeding (MTCT) and Cost Effectiveness Analysis of those Interventions
MS Sim, W  Cumberland, N Duan, Y J Bryson
(15IAC)
Abstract
 
Cost evaluation of PMTCT programmes
G Harms, S Theuring, A Mayer,  et al
 (15IAC)
Abstract
 
A comparison of economic analyses of nevirapine for prevention of mother to
child transmission of HIV
G Schmid, M Sweat, K O'Reilly, I de Zoysa, et al
 (14IAC)
Abstract
Viramune Donation Program